Incretin‐based therapy and the risk of diabetic foot ulcers and related events
Authors' conclusion
Incretin-based therapy was associated with a lower risk of DFU and DFU-related outcomes. This suggests benefits for the use of this treatment in people at risk of DFU.
Study context
- Population
- People with T2D starting treatment with metformin, Clinical Practice Research Datalink Aurum with hospital linkagematched cohorts: 98,770 and 25,422
- Exposure
- DPP-4i vs SU; GLP-1 RA vs insulin
- Outcome
- DFU
Methodological detailspropensity-score matched, new-user design, Clinical Practice Research Datalink Aurum with hospital data linkage
- Propensity-score matched
- New-user design
- Clinical Practice Research Datalink Aurum with hospital data linkage
Main finding
As reported in the abstract
Hazard ratio (95% CI)
DPP4-Isvs Sulphonylureas
0.88(0.79–0.97)
GLP1-RAsvs Insulinshort-term exposure (≤ 400 days)
0.44(0.32–0.60)
GLP1-RAsvs Insulinlong-term exposure (>400 days)
0.74(0.60–0.92)
Observational data: associations, not effects.
Further findings
Diabetic foot ulcer (DFU)-related hospitalization and mortality
- Risks of hospitalization and mortality lower with both DPP-4i use and GLP-1 RA use
Lower limb amputation (LLA)
- Risk of LLA lower with GLP-1 RA use
Sensitivity analyses
- Results consistent across several sensitivity analyses
Original publication
Incretin‐based therapy and the risk of diabetic foot ulcers and related events. Diabetes Obes Metab. Published 1 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →